A First-in-Human, Phase 1a/b, Dose-Escalation/Expansion Study of BG-68501, a Selective CDK2 Inhibitor, as Monotherapy or in Combination With Fulvestrant for Patients With HR+/HER2– Breast Cancer and Other Advanced Solid Tumors: First Disclosure of Clinical Data
June 24th 2025
Brian A. Van Tine, MD, PhD, presents results from the first-in-human Phase 1a trial of BG-68501, a selective CDK2 inhibitor, showing early signs of antitumor activity and a manageable safety profile in heavily pretreated patients with advanced solid tumors, including HR+/HER2– breast cancer and ovarian cancer, supporting continued dose escalation and ongoing enrollment.
